Immuneering (IMRX) Total Current Liabilities (2020 - 2024)
Immuneering (IMRX) has 5 years of Total Current Liabilities data on record, last reported at $6.9 million in Q3 2024.
- For Q3 2024, Total Current Liabilities rose 23.08% year-over-year to $6.9 million; the TTM value through Sep 2024 reached $6.9 million, up 23.08%, while the annual FY2023 figure was $7.8 million, 2.59% down from the prior year.
- Total Current Liabilities reached $6.9 million in Q3 2024 per IMRX's latest filing, up from $6.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $8.1 million in Q4 2022 and bottomed at $2.3 million in Q4 2020.
- Average Total Current Liabilities over 5 years is $5.6 million, with a median of $5.5 million recorded in 2023.
- Peak YoY movement for Total Current Liabilities: soared 149.74% in 2021, then decreased 22.51% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $2.3 million in 2020, then soared by 149.74% to $5.6 million in 2021, then skyrocketed by 42.96% to $8.1 million in 2022, then decreased by 2.59% to $7.8 million in 2023, then decreased by 11.8% to $6.9 million in 2024.
- Per Business Quant database, its latest 3 readings for Total Current Liabilities were $6.9 million in Q3 2024, $6.8 million in Q2 2024, and $5.2 million in Q1 2024.